Completed PHASE3 INTERVENTIONAL 2-arm NCT01916980

Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Eczema/Dermatitis and Dermal Pruritus (MK-4117-202)

A Phase III, Multicenter, Open-Label Long-Term Trial to Study the Efficacy and Safety of MK-4117 in Japanese Subjects With Eczema/Dermatitis and Dermal Pruritus.

Sponsor: Organon and Co

Conditions Dermal Pruritus Dermatitis Eczema

Interventions Desloratadine 5 mg

Updated 11 times since 2017 Last updated: Jun 5, 2024 Started: Aug 27, 2013 Primary completion: Mar 8, 2014 Completion: Mar 22, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Dermal Pruritus and Dermatitis, this trial is completed. The trial is conducted by Organon and Co and has accumulated 11 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

11 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jun 2024 — Jul 2024 [monthly]

Completed PHASE3
Mar 2022 — Jun 2024 [monthly]

Completed PHASE3
Jan 2021 — Mar 2022 [monthly]

Completed PHASE3

▶ Show 6 earlier versions

May 2019 — Jan 2021 [monthly]

Completed PHASE3
Dec 2018 — May 2019 [monthly]

Completed PHASE3
Jun 2018 — Dec 2018 [monthly]

Completed PHASE3
Nov 2017 — Jun 2018 [monthly]

Completed PHASE3
Feb 2017 — Nov 2017 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Aug 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Organon and Co

Data source: Organon and Co

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.